Active across 44 markets in four regions — served through a network of ~107 distributor partners. Building toward 120+ markets by 2028.
India HQ + 43 markets across four regions · active commercial supply, distribution and registration in progress
Every region operates through long-standing distributor partners — same cold-chain logistics, same WHO-GMP source, with country-specific regulatory adaptation by Regenix's regulatory affairs team.
Long-standing distributor partnerships across the corridor, with growing tender activity in the Philippines and Vietnam. Significant insulin demand growth region-wide.
Largest region by market count, anchored across North and East Africa. Active tender qualification in Egypt, Nigeria and Kenya for public-sector procurement.
Established footprint in Mexico, Brazil and Argentina. Country-specific dossier adaptations in progress for ANVISA, COFEPRIS and ANMAT registration pathways.
Sustained presence in Iraq, UAE and Saudi Arabia complemented by emerging CIS engagement across Russia, Kazakhstan and Uzbekistan.
Distributor, licensee or tender partner — we're evaluating new partnerships across the global footprint. Talk to our Business Development team.
Partnership models →